| |
|
|
ActiveHealth Management, Inc.
was acquired by Aetna Inc. in May 2005. Prior to the acquisition, ActiveHealth Management was a healthcare information technology and services company focused on improving the effectiveness of disease diagnosis and management. Key to the company's capabilities was proprietary software that integrated a wide array of clinical information with protocols and standards to elevate the quality of care in real time and reduce the overall cost for payors.
(www.activehealthmanagement.com) |
|
|
| |
|
|
Ambit Biosciences Corp.
is a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer. With more than 500 distinct kinases identified and over 30 kinase inhibitors in clinical trials or FDA approved, this important class of proteins is a rich area for therapeutic drug development.
(www.ambitbio.com) |
|
|
| |
|
|
AMICAS, Inc.
was acquired by VitalWorks, Inc. in November 2003. Prior to the acquisition, the company was engaged in the development and marketing of web-based Picture Archiving and Communication Systems "PACS" that provide diagnostic quality radiology image management services, including secure image capture, distribution, workflow integration and image archiving.
(www.amicas.com) |
|
|
| |
|
|
Amicus Therapeutics, Inc.
(NASDAQ:FOLD) is a biotechnology company developing small-molecule, orally-active drugs, known as Pharmacological Chaperones for treating human genetic disorders. Pharmacological chaperones are designed to help mutant proteins fold correctly into their normal 3-dimensional conformations, rescuing intrinsic biological activity and function.
(www.amicustherapeutics.com) |
|
|
| |
|
|
Athersys, Inc.
(NASDAQ:ATHX) is a biotechnology company focused on the development of small molecule and cell-based therapeutics for metabolic, cardiovascular and inflammatory indications. The company's lead product candidate, ATHX-105, is a highly selective agonist of the serotonin receptor 5HT2c, a validated molecular target located in the region of the brain that regulates appetite and food intake.
(www.athersys.com) |
|
|
| |
|
|
| BEI Medical Systems Company, Inc.
was acquired by Boston Scientific Corporation in June 2002. Prior to the acquisition, the
company was engaged in the manufacture and marketing of a new, proprietary and minimally invasive endometrial ablation system,
the Hydro ThermAblator ("HTA"), representing a major advance in the treatment of abnormal
uterine bleeding, a condition known as menorrhagia, that affects more than 10
million women in the U.S. annually. The HTA system received FDA approval and was commercially launched in 2001.
|
|
|
| |
|
|
Bio-Lok International, Inc.
was acquired by Healthpoint Capital in October 2006. Prior to the acquisition, the company
was engaged in the manufacturing and distribution of an innovative line of
dental implants and other products targeting the global oral surgery and general
dentistry markets. Bio-Lok's industry-leading and FDA approved dental implant
system, the Silhouette Laser-Lok™, utilizes a proprietary, laser micro-machined
surface (the Bio-Affinity Collar) to promote soft tissue and bone adherence while
preventing epithelial down-growth - major advancements in the field of esthetic dentistry.
(www.biolok.com)
|
|
|
| |
|
|
BioStorage Technologies, Inc.
is a leading provider of advanced
biomaterials storage, inventory management and worldwide cold-chain
logistics. The company serves pharmaceutical developers and
manufacturers, non-profit and corporate clinical research facilities,
donor organizations, forensic laboratories, universities, zoological and
veterinarian treatment and research facilities, healthcare and life
sciences companies.
(www.biostorage.com)
|
|
|
| |
|
|
CareGuide
(OTC:CGDE) provides disease and care management services to health plans, work/life benefits companies and self-funded employers.
(www.careguide.com)
|
|
|
| |
|
|
| Clinical Micro Sensors, Inc.
was acquired by Motorola in June 2001.
Prior to the acquisition, the company was engaged in the development of
DNA biochips aimed at enabling the delivery of
valuable genetic information to biomedical researchers,
physicians, and industrial users. |
|
|
| |
|
|
Comprehensive Neuroscience, Inc.
provides a full range of clinical trials management services with a focus on neuro-psychiatric and other central nervous system disorders. The company also provides behavioral health care-management services to public/government and private healthcare organizations.
(www.cnswebsite.com) |
|
|
| |
|
|
Conor Medsystems, Inc.
was acquired by Johnson & Johnson in January 2007. Prior to the acquisition, Conor was developing, manufacturing and marketing next generation drug
eluting stents. The company's initial focus was on the treatment of coronary restenosis. Conor completed an IPO in December 2004.
(www.conormed.com)
|
|
|
| |
|
|
Corus Pharma, Inc.
was acquired by Gilead Sciences in August 2006. Prior to the acquisition, Corus was developing small molecule drugs for the treatment of respiratory diseases.
(www.coruspharma.com)
|
|
|
| |
|
|
EyeTel Imaging, Inc.
was acquired by NeuroMetrix, Inc. in December 2007. Prior to the acquisition, the company was commercializing a proprietary retinal-imaging device that empowers primary care physicians and optometrists to rapidly and cost-effectively diagnose diabetic retinopathy and other leading causes of preventable blindness. EyeTel's innovative business model included a clinical partnership with Johns Hopkins' Wilmer Eye Institute.
(www.eyetel-imaging.com)
|
|
|
| |
|
|
Heartscape Technologies, Inc.
is engaged in the development and marketing of the PRIME ECG®
Electrocartography System, an FDA approved medical device that accurately
and rapidly diagnoses heart attacks and ischemia in the emergency room setting -
enabling earlier invention, a central factor in reducing patient death and morbidity.
(www.primeecg.com)
|
|
|
| |
|
|
Health Language, Inc.
is a healthcare information technology company engaged in the development and marketing of a proprietary middleware application
called LE (Language Engine) that automates the incorporation of controlled medical vocabulary and coding standards
into healthcare IT applications. The principal benefits of this application are substantially
improved decision support systems and more efficient and accurate computerized order entry that can lead to a reduction in
medical errors and improved patient safety.
(www.healthlanguage.com)
|
|
|
| |
|
|
Impliant, Inc.
is a medical device company positioned to become a leader in the emerging field of motion preserving spinal implants. The company's initial focus is on the development of the TOPS™ System, a total posterior motion preservation system that addresses multiple sources of back pain.
(www.impliant.com)
|
|
|
| |
|
|
Medingo Ltd.
is a medical device company developing next generation insulin dispensing and glucose monitoring technologies for patients with diabetes. Medingo's initial product, The Solo™, is one of the first products in a new category of insulin pumps called
"dispensing patches" that will address the shortcomings of traditional larger
"pager-like" pumps.
(www.medingo.com)
|
|
|
| |
|
|
NuGEN Technologies, Inc.
is a life sciences research tools company developing and marketing powerful technology for efficient and cost-effective amplification of nucleic acids (DNA and RNA), a critical rate limiting step in genomics research for the identification of new drugs and drug targets.
(www.nugentechnologies.com)
|
|
|
| |
|
|
Rib-X Pharmaceuticals, Inc.
is a biotechnology company focused on the structure-based design of new classes of antibiotics. The company's underlying drug discovery
engine capitalizes on its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential
role in the fundamental process of protein synthesis. Rib-X has multiple drug candidates in clinical and preclinical development targeting
some of the leading causes of serious community and hospital-acquired infectious diseases.
(www.rib-x.com)
|
|
|
| |
|
|
Targanta Therapeutics, Inc. (NASDAQ:TARG) is a biotechnology company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Targanta's lead drug candidate, Oritavancin, has completed two Phase III clinical trials in complicated skin and skin structure infections and is under study for additional indications and unique treatment regimens.
(www.targanta.com)
|
|
|
| |
|
|
U-Systems, Inc.
designs, develops, manufactures and markets innovative, ultrasound
systems and software to assist the radiologist in detection of breast cancer in women
with dense breast tissue. The Company's first product, the Full-Field Breast Ultrasound
System™ (FFBU™) automatically scans the whole-breast and presents the results to the
physician in a mammogram-like format (Somogram™) - enabling high volume, cost-effective
ultrasound imaging.
(www.u-sys.com)
|
|
|
| |
|
|
ZettaCore, Inc.
is a nanotechnology company using organic molecules as the primary component of ultra high density, low power molecular
memory arrays and devices.
(www.zettacore.com)
|
|
|
| |
|
|
